ARTICLE | Company News
Praecis submits NDA for abarelix
December 13, 2000 8:00 AM UTC
PRCS submitted an NDA to the FDA for abarelix depot, a luteinizing hormone releasing hormone (LHRH)/gonadotropin releasing hormone (GnRH) antagonist to treat prostate cancer. PRCS is developing abarel...